AI-powered humanoid robot joins drug discovery labs
Interesting Engineering - 06-Mar-2025Insilico’s "Supervisor" robot automates lab work and speeds up drug discovery
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company that uses artificial intelligence to develop new drugs and for aging research
Visit website: https://insilico.com/
Details last updated 09-Apr-2019
Insilico’s "Supervisor" robot automates lab work and speeds up drug discovery
Researchers call for better data quality, transparency, and standardization
Ongoing clinical trials aim to confirm its effectiveness in human therapies
Insilico’s ISM001-055 outperforms rapamycin in reducing inflammation and restoring cellular function
Traditional methods take years, but this new approach is much quicker
CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation
Computer scientist and professor at the Courant Institute of Mathematical Sciences of New York University
Former Chief Scientific Officer at Sequenom and member of Scientific Advisory Board at Insilico Medicine
Chairman and CEO at Sinovation Ventures and President at Sinovation Ventures Artificial Intelligence Institute
Alex Zhavoronkov presented methylation clocks and AI models as groundbreaking tools
31-Aug-2021 to 03-Sep-2021
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
AI to track the rate of ageing at the molecular, cellular, tissue, organ, system, physiological, and psychological levels
Alex Zhavoronkov delivered a keynote on AI-Guided End-to-End Drug Discovery
Alex Zhavoronkov discusses a generative AI breakthrough in drug discovery
Alex Zhavoronkov pioneers AI-powered drug development
Chief Scientist and Chief Operating Officer at Deep Longevity and Head of Biomarker Development at Insilico Medicine.